Inovio Pharmaceuticals Announces 2024 Annual Meeting of Stockholders

Ticker: INO · Form: DEF 14A · Filed: Apr 11, 2024 · CIK: 1055726

Inovio Pharmaceuticals, INC. DEF 14A Filing Summary
FieldDetail
CompanyInovio Pharmaceuticals, INC. (INO)
Form TypeDEF 14A
Filed DateApr 11, 2024
Risk Levellow
Pages16
Reading Time19 min
Sentimentneutral

Sentiment: neutral

Topics: proxy statement, annual meeting, virtual meeting, stockholders, INOVIO

TL;DR

<b>Inovio Pharmaceuticals will host its 2024 Annual Meeting of Stockholders virtually on May 21, 2024, with online access starting at 9:00 a.m. ET.</b>

AI Summary

INOVIO PHARMACEUTICALS, INC. (INO) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. Inovio Pharmaceuticals, Inc. will hold its virtual Annual Meeting of Stockholders on May 21, 2024, at 9:00 a.m. Eastern Time. Stockholders can attend the virtual meeting by accessing www.virtualshareholdermeeting.com/INO2024 using a 16-digit control number. For those holding shares in 'street name', specific instructions from brokers or nominees are required to obtain the control number or attend. A list of stockholders of record will be available for examination from May 10, 2024, until the meeting by emailing investor.relations@inovio.com. The meeting will not be held in person, but the virtual format ensures stockholders have the same participation rights.

Why It Matters

For investors and stakeholders tracking INOVIO PHARMACEUTICALS, INC., this filing contains several important signals. The shift to a virtual-only meeting format impacts how shareholders can participate and requires specific access procedures, potentially affecting engagement. The availability of a stockholder list for examination and the need for control numbers highlight the procedural requirements for shareholder participation and voting.

Risk Assessment

Risk Level: low — INOVIO PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) for an annual meeting, containing standard procedural information and no new material financial or strategic disclosures.

Analyst Insight

Review the proxy statement for details on proposals to be voted on at the annual meeting, including any director elections or corporate governance changes.

Key Numbers

Key Players & Entities

FAQ

When did INOVIO PHARMACEUTICALS, INC. file this DEF 14A?

INOVIO PHARMACEUTICALS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 11, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by INOVIO PHARMACEUTICALS, INC. (INO).

Where can I read the original DEF 14A filing from INOVIO PHARMACEUTICALS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by INOVIO PHARMACEUTICALS, INC..

What are the key takeaways from INOVIO PHARMACEUTICALS, INC.'s DEF 14A?

INOVIO PHARMACEUTICALS, INC. filed this DEF 14A on April 11, 2024. Key takeaways: Inovio Pharmaceuticals, Inc. will hold its virtual Annual Meeting of Stockholders on May 21, 2024, at 9:00 a.m. Eastern Time.. Stockholders can attend the virtual meeting by accessing www.virtualshareholdermeeting.com/INO2024 using a 16-digit control number.. For those holding shares in 'street name', specific instructions from brokers or nominees are required to obtain the control number or attend..

Is INOVIO PHARMACEUTICALS, INC. a risky investment based on this filing?

Based on this DEF 14A, INOVIO PHARMACEUTICALS, INC. presents a relatively low-risk profile. The filing is a routine proxy statement (DEF 14A) for an annual meeting, containing standard procedural information and no new material financial or strategic disclosures.

What should investors do after reading INOVIO PHARMACEUTICALS, INC.'s DEF 14A?

Review the proxy statement for details on proposals to be voted on at the annual meeting, including any director elections or corporate governance changes. The overall sentiment from this filing is neutral.

How does INOVIO PHARMACEUTICALS, INC. compare to its industry peers?

INOVIO Pharmaceuticals, Inc. operates in the biotechnology sector, focusing on developing DNA-based vaccines and therapies.

Are there regulatory concerns for INOVIO PHARMACEUTICALS, INC.?

This filing is a Schedule 14A (DEF 14A), a proxy statement required by the SEC for public companies to solicit shareholder votes.

Industry Context

INOVIO Pharmaceuticals, Inc. operates in the biotechnology sector, focusing on developing DNA-based vaccines and therapies.

Regulatory Implications

This filing is a Schedule 14A (DEF 14A), a proxy statement required by the SEC for public companies to solicit shareholder votes.

What Investors Should Do

  1. Verify eligibility and obtain the 16-digit control number for virtual meeting access.
  2. Review the Notice of Annual Meeting of Stockholders for details on formal business and proposals.
  3. Check the company's investor relations website for any updates prior to the meeting date.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard proxy statement for an annual meeting, providing procedural information for stockholders.

Filing Stats: 4,763 words · 19 min read · ~16 pages · Grade level 9.3 · Accepted 2024-04-11 16:10:04

Filing Documents

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 17 Executive Officers and Other Information 19

Executive Compensation 22

Executive Compensation 22 Director Compensation 41 Proposal 2 Ratification of Appointment of Independent Registered Public Accounting Firm 43 Proposal 3 Non-Binding, Advisory Vote on Executive Compensation 45 Stockholder Proposals 46 Annual Report 47 Transaction of Other Business 48 Inovio Pharmaceuticals, Inc. iii 2024 Proxy Statement PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS The Board of Directors of Inovio Pharmaceuticals, Inc. (the "Board") is soliciting proxies for use at the Annual Meeting of Stockholders to be held virtually over the internet, on May 21, 2024 at 900 a.m. Eastern Time, or any adjournment thereof, for the purposes set forth in the accompanying Notice of Annual Meeting. This Proxy Statement is dated April 11, 2024. We are mailing this Proxy Statement to our stockholders on or about April 11, 2024. Unless the context requires otherwise, references to "we," "us," "our," "Inovio," and "Company" refer to Inovio Pharmaceuticals, Inc. General Information Voting Securities Only stockholders of record as of the close of business on March 25, 2024 will be entitled to vote at the meeting and any adjournment thereof. As of March 25, 2024, we had the following outstanding* 23,370,365 shares of common stock 9 shares of Series C Cumulative Convertible Preferred Stock , which are convertible into an aggregate of 275 shares of common stock. Number of Votes You may vote online at the meeting or using the automated Internet or phone system or by proxy. On the proposals presented in this Proxy Statement, each holder of shares of our 1 vote Common stock is entitled to one vote for each share of stock held. 30 votes Series C Preferred Stock is entitled to 30 votes for each share of Series C Preferred Stock held. Holders of our common stock and Series C Preferred Stock vote together as a single class in connection with each of Proposal Nos. 1, 2 and 3. Our bylaws provide that one-third of all of the shares of the stock

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing